Save the dates: ZEISS Quality Innovation Summit, October 22-24

Embark on a journey to the future of metrology.

Wusson Accelerator AB

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Takeover bid is being completed – Japanese company acquires Calliditas

Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided...

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

Pulsen på patientförbunden del 4: Ung Cancer

”Engagemang och vilja finns, det gäller bara att hitta rätt former”, säger Therese Leijon, Ung Cancer, i Life Science Swedens artikelserie Pulsen på patientförbunden.

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

SupraCube - In life Science

Superconductors must be permanently kept below their transition temperature for levitation. Because of the integrated cooler, applications with superconductors ...

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Compact and leak-tight powerhouse

Media-separated solenoid valve VYKA from Festo is virtually leak-free

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Hypothesis testing versus conspiracy theory

"How do you know what is a conspiracy theory and what is a reasonable, scientifically based conclusion?" In a column, Ingrid Lönnstedt reflects on this question.

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

EMA säger nej till Eli Lillys alzheimerläkemedel

Den europeiska läkemedelsmyndigheten EMA rekommenderar att Eli Lillys alzheimerkandidat Kisunla nekas godkännande i EU. Nyttan med behandlingen bedöms inte över...

“We need to build flexible operating theatres”

Flexible operating theatres, micro-sensors on surgeons to monitor their well-being and 3D images projected onto organs to be operated on. These are a few ideas ...

VGR pausar Millennium på obestämd tid

Under kaosartade former stoppades journalsystemet Millennium i höstas. Nu pausas införandet på obestämd tid, men Västra Götalandsregionen utesluter inte ett åte...

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

A vaccine the world is waiting for: “It can change the lives of many”

A Solna laboratory is developing a vaccine that could save the lives of countless children in low- and middle-income countries. “Working on something that can m...

“Life science is important on a personal level”

From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of ...

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

Pneumatics Makes a Technological Leap with Piezo

The first high-precision proportional valve terminal VTEP opens up new application areas

Regeringens utredare: Avveckla Vetenskapsrådet, Vinnova, Formas och Forte

Idag, onsdag, läggs ett förslag till regeringen som innebär att dagens struktur för forskningsfinansiering avvecklas och tre helt nya myndigheter bildas.

MSD discontinues development of cancer drugs after trial failures

MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.